CEM Store
Registered
Letrozole belongs to a class of compounds known as aromatase inhibitors. What exactly is aromatase? Aromatase is an enzyme that is responsible for the conversion of testosterone to estrogen. This occurs when the aromatase enzyme binds to testosterone. This binding begins the conversion, or aromatization, of testosterone to estrogen. There is a specific site on the aromatase enzyme where this binding to testosterone occurs. It is at this site where Letrozole wields its influence. It prevents the binding of the aromatase enzyme to testosterone - preventing the conversion to estrogen.
Letrozole is an extremely powerful aromatase inhibitor. At its standard dose of 2.5mg/day for research purposes it has been demonstrated to reduce estrogen in excess of an astounding 98%! If one were to use such a powerful aromatase inhibitor in their research subjects to manage elevated estrogen, an effective dosage could be expected to be as low as .25 mg every other day.
There is also ample evidence that letrozole is an effective tool in research subjects when it comes to the treatment of gynecomastia. Gynecomastia is the abnormal growth of breast tissue in males. This growth is primarily caused by excess levels of estrogen. In the absence of estrogen this breast tissue can not survive. Letrozole is so efficient at the reduction of circulating estrogen it has proven effective in the treatment of gynecomastia.
There are a few compounds we as researchers should consider having on hand at all times. Letrozole is a compound that falls into that category. It is so efficient at what it does it can be an invaluable tool when it comes to treating rapidly elevated levels of estrogen or even the starting signs of gynecomastia. Many have also managed to very effectively use it as an estrogen management tool in their research. It is a solid, multi-use compound that is by far the most effective in its class at reducing estrogen.
Get it here Letrozole 30mL 2.5mg/mL
Refs:
*Clin Cancer Res. 2005 Apr 15;11(8):2809-21
*J Clin Oncol. 2012 Aug 20;30(24):2977-80. doi: 10.1200/JCO.2012.42.0273. Epub 2012 Jul 16.Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. Folkerd EJ, Dixon JM, Renshaw L, A'Hern RP, Dowsett M.Source Royal Marsden Hospital, London, United Kingdom. Elizabeth.Folkerd@icr.ac.uk
*J Steroid Biochem Mol Biol. 2001 Dec;79(1-5):27-34. Aromatase overexpression transgenic mice model: cell type specific expression and use of letrozole to abrogate mammary hyperplasia without affecting normal physiology.Mandava U, Kirma N, Tekmal RR.Department of Gynecology and Obstetrics, Emory University, 4217 Woodruff Memorial Building, 1639 Pierce Drive, Atlanta, GA 30322-4710, USA.
Letrozole 30mL 2.5mg/mL
Letrozole is an extremely powerful aromatase inhibitor. At its standard dose of 2.5mg/day for research purposes it has been demonstrated to reduce estrogen in excess of an astounding 98%! If one were to use such a powerful aromatase inhibitor in their research subjects to manage elevated estrogen, an effective dosage could be expected to be as low as .25 mg every other day.
There is also ample evidence that letrozole is an effective tool in research subjects when it comes to the treatment of gynecomastia. Gynecomastia is the abnormal growth of breast tissue in males. This growth is primarily caused by excess levels of estrogen. In the absence of estrogen this breast tissue can not survive. Letrozole is so efficient at the reduction of circulating estrogen it has proven effective in the treatment of gynecomastia.
There are a few compounds we as researchers should consider having on hand at all times. Letrozole is a compound that falls into that category. It is so efficient at what it does it can be an invaluable tool when it comes to treating rapidly elevated levels of estrogen or even the starting signs of gynecomastia. Many have also managed to very effectively use it as an estrogen management tool in their research. It is a solid, multi-use compound that is by far the most effective in its class at reducing estrogen.
Get it here Letrozole 30mL 2.5mg/mL
Refs:
*Clin Cancer Res. 2005 Apr 15;11(8):2809-21
*J Clin Oncol. 2012 Aug 20;30(24):2977-80. doi: 10.1200/JCO.2012.42.0273. Epub 2012 Jul 16.Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. Folkerd EJ, Dixon JM, Renshaw L, A'Hern RP, Dowsett M.Source Royal Marsden Hospital, London, United Kingdom. Elizabeth.Folkerd@icr.ac.uk
*J Steroid Biochem Mol Biol. 2001 Dec;79(1-5):27-34. Aromatase overexpression transgenic mice model: cell type specific expression and use of letrozole to abrogate mammary hyperplasia without affecting normal physiology.Mandava U, Kirma N, Tekmal RR.Department of Gynecology and Obstetrics, Emory University, 4217 Woodruff Memorial Building, 1639 Pierce Drive, Atlanta, GA 30322-4710, USA.
Letrozole 30mL 2.5mg/mL
